Drug companies are suspending further investments in Poland, largely because of a new medical reimbursement scheme that is creating financial difficulties for drug firms, said Michał Pilkiewicz of the research firm IMS Health. Future pharmaceutical investments remain unlikely because of the reimbursement law and uncertainty over any national strategy by the government's National Health Fund, he said.

Related Summaries